Francis L J, Houston J B, Hallifax D
Centre for Applied Pharmacokinetic Research, Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom.
Centre for Applied Pharmacokinetic Research, Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom
Drug Metab Dispos. 2021 Mar;49(3):188-201. doi: 10.1124/dmd.120.000294. Epub 2020 Dec 18.
Plasma protein-mediated uptake (PMU) and its effect on clearance (CL) prediction have been studied in various formats; however, a comprehensive analysis of the overall impact of PMU on CL parameters from hepatocyte assays (routinely used for IVIVE) has not previously been performed. The following work collated data reflecting the effect of PMU for 26 compounds with a wide variety of physicochemical, drug, and in vivo CL properties. PMU enhanced the unbound intrinsic clearance in vitro (CL) beyond that conventionally calculated using fraction unbound and was correlated with the unbound fraction of drug in vitro and in plasma (fu) and absolute unbound intrinsic clearance in vivo (CL) in both rat and human hepatocytes. PMU appeared to be more important for highly bound (fu < 0.1) and high CL drugs. These trends were independent of species, assay conditions, ionization, and extended clearance classification system group, although the type of plasma protein used in in vitro assays may require further investigation. Such generalized trends (spanning fu 0.0008-0.99) may suggest a generic mechanism behind PMU; however, multiple drug-dependent mechanisms are also possible. Using the identified relationship between the impact of PMU on CL and fu, PMU-enhanced predictions of CL were calculated for both transporter substrates and metabolically cleared drugs. PMU was accurately predicted, and incorporation of predicted PMU improved the IVIVE of hepatic CL, with an average fold error of 1.17 and >50% of compounds predicted within a 2-fold error for both rat and human data sets ( ≥ 100). SIGNIFICANCE STATEMENT: Current strategies for prediction of hepatic clearance from in vitro data are recognized to be inaccurate, but they do not account for PMU. The impact of PMU on CL is wide ranging and can be predicted based on fraction unbound in plasma and applied to CL values obtained by standard procedures in the absence of plasma protein. Such PMU-enhanced predictions improved IVIVE, and future studies may easily incorporate this PMU relationship to provide more accurate IVIVE.
血浆蛋白介导的摄取(PMU)及其对清除率(CL)预测的影响已在多种形式中进行了研究;然而,此前尚未对PMU对肝细胞试验(常用于体内外外推法)中CL参数的总体影响进行全面分析。以下工作整理了反映26种具有广泛物理化学、药物和体内CL特性的化合物的PMU效应的数据。PMU提高了体外未结合内在清除率(CL),超出了传统上使用未结合分数计算的值,并且与大鼠和人肝细胞中药物的体外和血浆未结合分数(fu)以及体内绝对未结合内在清除率(CL)相关。PMU似乎对高结合(fu < 0.1)和高CL药物更为重要。尽管体外试验中使用的血浆蛋白类型可能需要进一步研究,但这些趋势与物种、试验条件、离子化和扩展清除率分类系统组无关。这种普遍趋势(涵盖fu 0.0008 - 0.99)可能暗示了PMU背后的一般机制;然而,多种药物依赖性机制也是可能的。利用所确定的PMU对CL和fu的影响之间的关系,计算了转运体底物和代谢清除药物的PMU增强的CL预测值。PMU得到了准确预测,并且纳入预测的PMU改善了肝脏CL的体内外外推法结果,大鼠和人类数据集(≥100)的平均倍数误差为1.17,超过50%的化合物预测误差在2倍以内。意义声明:目前从体外数据预测肝脏清除率的策略被认为不准确,但它们没有考虑PMU。PMU对CL的影响广泛,可以基于血浆中的未结合分数进行预测,并应用于在无血浆蛋白情况下通过标准程序获得的CL值。这种PMU增强的预测改善了体内外外推法结果,未来的研究可能很容易纳入这种PMU关系以提供更准确的体内外外推法结果。